Salarius Pharmaceuticals, Inc.
SLRX
$0.84
-$0.02-2.03%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.00M | -5.10M | -5.57M | -5.58M | -4.99M |
| Total Depreciation and Amortization | 4.40K | 4.40K | 4.40K | 4.40K | 4.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 130.50K | 167.70K | 229.70K | 273.70K | 308.10K |
| Change in Net Operating Assets | 436.60K | 788.10K | 982.80K | 772.30K | -612.90K |
| Cash from Operations | -4.43M | -4.14M | -4.35M | -4.53M | -5.29M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -200.00K | -- | -- | -- | -- |
| Cash from Investing | -200.00K | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -328.80K | -398.70K | -403.40K | -466.60K | -529.00K |
| Issuance of Common Stock | 6.52M | 2.09M | 2.18M | 1.53M | 1.53M |
| Repurchase of Common Stock | -29.00K | -29.00K | -- | -- | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6.16M | 1.67M | 1.78M | 1.06M | 997.50K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.53M | -2.48M | -2.57M | -3.47M | -4.30M |